Molecular Oncology
Volume 1, Issue 4 , Pages 406-412, April 2008

Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib☆

  • Gary M. Clark

      Affiliations

    • Corresponding Author InformationTel.: +1 303 546 7633; fax: +1 303 546 7889.

Biostatistics and Data Management, OSI Pharmaceuticals, Inc., 2860 Wilderness Place, Boulder, CO 80301, USA

Received 11 November 2007; received in revised form 3 December 2007; accepted 4 December 2007. published online 03 January 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Presented in part at the 13th Danish Cancer Society Symposium: From the Bench to the Bedside and Back, Copenhagen, Denmark, August 27–29, 2007.

PII: S1574-7891(07)00102-0

doi:10.1016/j.molonc.2007.12.001

Molecular Oncology
Volume 1, Issue 4 , Pages 406-412, April 2008

Article Tools

* Image Usage & Resolution